Ipilimumab and stereotactic radiosurgery with cyberknife® system in melanoma brain metastases: A retrospective monoinstitutional experience

Valentina Borzillo, Rossella Di Franco, Diana Giannarelli, Fabrizio Cammarota, Esmeralda Scipilliti, Emma D’ippolito, Angela Petito, Marcello Serra, Sara Falivene, Antonio M. Grimaldi, Ester Simeone, Lucia Festino, Vito Vanella, Claudia Trojaniello, Maria Grazia Vitale, Gabriele Madonna, Paolo A. Ascierto, Paolo Muto

Research output: Contribution to journalArticlepeer-review

Abstract

The median overall survival (OS) and local control (LC) of patients with melanoma brain metastases (MBMs) are poor even with immune checkpoint inhibitors and/or radiotherapy (RT). The aims of the study were to evaluate the association and timing of stereotactic radiotherapy (SRT)/radiosurgery (SRS) performed with the CyberKnife® System and ipilimumab (IPI). A total of 63 MBMs patients were analyzed: 53 received RT+IPI and 10 RT alone. Therefore, the patients were divided into four groups: RT PRE-PI (>4 weeks before IPI) (18), RT CONC-IPI (4 weeks before/be-tween first and last cycle/within 3 months of last cycle of IPI) (20), RT POST-IPI (>3 months after IPI) (15), and NO-IPI (10). A total of 127 lesions were treated: 75 with SRS (one fraction) and 24 with SRT (three to five fractions). The median follow-up was 10.6 months. The median OS was 10.6 months for all patients, 10.7 months for RT+IPI, and 3.3 months for NO-IPI (p = 0.96). One-year LC was 50% for all patients, 56% for RT+IPI, and 18% for NO-IPI (p = 0.08). The 1-year intracranial control was 45% for all patients, 44% for RT+IPI, and 51% for NO-IPI (p = 0.73). IPI with SRS/SRT in MBMs treatment could improve LC. However, the impact and timing of the two modalities on pa-tients’ outcomes are still unclear.

Original languageEnglish
Article number1857
JournalCancers
Volume13
Issue number8
DOIs
Publication statusPublished - Apr 2 2021

Keywords

  • CyberKnife
  • Ipilimumab
  • Melanoma brain metastases
  • Radiosurgery
  • Stereotactic radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Ipilimumab and stereotactic radiosurgery with cyberknife® system in melanoma brain metastases: A retrospective monoinstitutional experience'. Together they form a unique fingerprint.

Cite this